Initiate the GRECO-2 clinical trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- May 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“GRECO-2 Initiate Trial Pancreatic Cancer GC4711 vs. placebo 1H 2021”
What we found
Evidence strength A What the grades mean
The company initiated the GRECO-2 clinical trial in May 2021, which is within the first half of 2021 deadline.
-
A Galera Therapeutics, Inc. 10-Q filed 2021-08-10
“We initiated a Phase 2b trial of GC4711 in combination with SBRT in patients with LAPC in May 2021, which we refer to as the GRECO-2 trial.” ✓ confirmed on the page
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- GRECO-2 trial initiation
- In the company’s control
- Medium
- Specificity
- High
- Depends on
- Customer
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Galera Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C563577-021136 · Corrections policy